Offering innovative solutions with high added value to drug delivery formulation issues.

APTYS is a CRO spin-off of the University of Auvergne in Clermont-Ferrand, specialized in drug delivery. Funded in 2002, the company acquired patents rights on pharmaceutical technologies from the University.

Aptys’ business model is based on contract service. We guaranty reactivity and expertise to our customers, in the resolution of technological problems under cost control. The generated turnover is reinvested on internal research, which in turn feeds our technologies pipeline.

The core business of APTYS is drug delivery.

Our dosage forms include: tablets; inhaled forms; foams; semi-solid forms; implants; microspheres

finding applications in

ophtalmology; dermatology; pneumology; gastroenterology; oncology; infectiology; pediatrics.

Our services are adapted to various strategies: formulation of new chemical entities and peptides/proteins, reformulation of registered molecules and development of drug delivery systems. We also offer support services such as: analytical development, dissolution studies, ICH stability studies and ADME studies (PK/PD).

Download BROCHURE